Opko Health, Inc.

Good day and welcome to the OpcoHealth fourth quarter 2024 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead.

Thank you, Operator. Good afternoon. This is Yvonne Briggs with Alliance Advisors IR. Thank you all for joining today's call to discuss Opco Health's financial results for the fourth quarter of 2024. I'd like to remind you that any statements made during this call by management, other than statements of historical fact, will be considered forward-looking and, as such, will be subject to risks and uncertainties that could materially affect the company's expected results. These forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the soon-to-be-filed annual report on Form 10-K for the year ended December 31, 2024, and in subsequently filed SEC reports. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, February 27, 2025. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Before we begin, let me review the format for today's call. Dr. Philip Frost, Chairman and Chief Executive Officer, will open the call. Dr. Elias Zerhouni, vice chairman and president, will then provide an overview of Opco's pharmaceutical business and bioreference health, as well as discuss progress with the MODEX pipeline. After that, Adam Local, Opco's CFO, will review the company's fourth quarter financial results and discuss this year's financial outlook. And then we'll open up the call for questions. Now I'd like to turn the call over to Dr. Frost.

Good afternoon. and thank you for joining us today. 2024 was a transformative year for Opco, and I'm confident about our prospects for the year ahead. MODX made great strides to advance its pipeline as two programs entered phase one clinical trials. We believe MODX's proprietary technology platforms hold tremendous promise, and we look forward to continued progress with its multi-specific antibody technology and its nanoparticle vaccine platform. Elias will provide more detail on the specific programs in a moment. Our product developed pipeline also includes our once-weekly injectable dual GLP-1 glucagon agonist, APCO-88006, which continues to show encouraging clinical pharmacology data in diabetic and metabolic mice models. A promising orally bioavailable once-daily form has been an animal test by our partner, Entero Bio. We expect both sub-Q and orally delivered forms to be IND ready by the end of the year. Pfizer continues to make progress on its global commercialization of Angenla, with sales presently growing in 42 countries. Elias and Adam will address in more detail. In reality, our partner in China, Nikoya, is anticipating a strong launch during 2025. From a financial point of view, we relined our up-goes capital structure to be in a strong position. With the infusion of cash from various transactions, we are adequately funded to advance our pharmaceutical pipeline and to return capital to our shareholders through common stock and convertible Note repurchases. We're executing our strategy and achieving significant milestones. As I mentioned last quarter, we are managing segments of our business to drive value for OPCO through additional partnerships, business development initiatives, and asset sales. We're confident that our current business prospects and strategy will continue to add value as we execute on this strategy. We expect 2025 to be a year of progress in all aspects of our business. In all, a good year. With that overview, I'll turn the call over to Elias.